HU Jing,WU Xue,RUAN Yan,et al.Clinical Comprehensive Evaluation of Jinsang Kaiyin Preparation in Treatment of Acute Pharyngitis/Laryngitis[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(14):96-104.
HU Jing,WU Xue,RUAN Yan,et al.Clinical Comprehensive Evaluation of Jinsang Kaiyin Preparation in Treatment of Acute Pharyngitis/Laryngitis[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(14):96-104. DOI: 10.13422/j.cnki.syfjx.20231290.
Clinical Comprehensive Evaluation of Jinsang Kaiyin Preparation in Treatment of Acute Pharyngitis/Laryngitis增强出版
To comprehensively evaluate the clinical application value of four types of Jinsang Kaiyin preparation(JSKYs) and the other two Chinese patent medicines(CPMs) in the treatment of acute pharyngitis/laryngitis,so as to provide evidence for their rational clinical use and regulatory decision-making.
Method
2
According to the guideline for clinical comprehensive evaluation of CPM,the effectiveness,safety,economy,innovation,suitability and accessibility of four JSKYs and the other two CPM in the treatment of acute pharyngitis/laryngitis were comprehensively evaluated,which were ranked based on the quantitative scoring tool.
Result
2
① Effectiveness:Compared with the control group,JSKYs can improve the total effectiveness rate of acute pharyngitis/laryngitis and improve the symptoms. Network meta-analysis showed that the probability of JSKY ranked the first in terms of total effectiveness rate.② Safety:JSKYs did not show acute toxicity and long-term toxicity. The main adverse reactions were skin rash,abdominal pain,diarrhea,nausea and vomiting,etc,which were similar with the other two CPM.③ Economy:For patients with acute laryngitis(wind heat syndrome),compared with drug A,JinsangKaiyin capsule has the comparable cost-effectiveness. For patients with acute pharyngitis(wind heat syndrome),compared with drug B,JinsangKaiyin capsul has low cost and better effectiveness.④ Innovation:Compared with the other two CPM,the indications of JSKYs have their own unique population. JSKYs have six patent approval certifications and has been approved for sale in the Philippines.⑤ Suitability:Compared with the other two CPM,the investigated doctors,pharmacists and patients all believed that the instruction of JSKY was clearer and easier to understand,the use and storage conditions were more convenient,etc.⑥ Accessibility:JSKYs are included in the category B of the
National Basic Medical Insurance
(2022 edition),which has good cost-effectiveness and affordability for medical insurance and self paid patients. JSKYs do not contain endangered animals and plants. The supply of raw materials can meet the demand of production at present.
Conclusion
2
As for the drug value calculation,JSKY obtained the highest score. Based on all dimensions of evidence,expert consensus on JSKY is class A,which can be directly converted into decision making.
关键词
中成药临床综合评价卫生技术评估金嗓开音制剂急性咽炎急性喉炎
Keywords
clinical comprehensive evaluation of Chinese patent medicinehealth technology assessmentJinsangKaiyin preparationacute pharyngitisacute laryngitis
references
孙虹,张罗.耳鼻咽喉头颈外科学[M].9版.北京:人民卫生出版社,2019.
DI MUZIO F,BARUCCO M,GUERRIERO F.Diagnosis and treatment of acute pharyngitis/tonsillitis:A preliminary observational study in General Medicine[J].Eur Rev Med Pharmacol Sci,2016,20(23):4950-4954.
GUYATT G H,OXMAN A D,VIST G E,et al.GRADE:An emerging consensus on rating quality of evidence and strength of recommendations[J].BMJ,2008,336(7650):924-926.
A Multicenter Clinical Trial of Pudilan Anti-inflammatory Oral Liquid of Different Doses in Treatment of Acute Pharyngitis/Tonsillitis Caused by Bacterial Infection in Adults
Health Technology Assessment Institutions and Organizations: A Scoping Review
Feasibility Analysis of EVIDEM Framework in Health Technology Assessment of Traditional Chinese Medicine
Usage and Dosage of Kaihoujian Throat Spray (for Children) in Treatment of Acute Pharyngitis and Acute Tonsillitis
Clinical Observation of Qiaohe Plus Decoction for Treating Acute Pharyngitis
Related Author
CUI Yinghai
LI Dinglei
YU Xuefeng
PANG Min
ZHANG Wei
MA Zhanping
ZHANG Nianzhi
HUANG Tao
Related Institution
Shuguang Hospital,Shanghai University of TCM
Jichuan Pharmaceutical Group Co.Ltd.
The Fourth Affiliated Hospital of China Medical University
First Affiliated Hospital, Heilongjiang University of Chinese Medicine